Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ChiCTR2000041242Phase 4Recruiting
Phase 4, randomised trial of dasatinib in chronic myelogenous leukemia (CML) (2 arms), sponsored by Union Hospital. Primary endpoints: CCyR rate at 12 months, MMR rate at 12 months and 2 more. Started Jul 2019; status: recruiting.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on ChiCTR2000041242.